Clinical Trial Update: Post-Market Evaluation of the EVO ICL [NA]

View source ↗

Summary

Post-market evaluation of the EVO ICL for myopia and myopic astigmatism has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myopia
• Myopic Astigmatism

Drugs mentioned

• EVO-ICL

Snippet

Sponsor: Staar Surgical Company | Conditions: Myopia, Myopic Astigmatism | NA | Status: COMPLETED | Results posted: 2024-12-03